Satellos Bioscience (MSLE) Total Current Liabilities (2023 - 2026)
Satellos Bioscience (MSLE) posted quarterly Total Current Liabilities of $4.6 million for Q1 2026, up 11.16% quarter-over-quarter from $4.1 million in Q4 2025.
Satellos Bioscience (MSLE) Total Current Liabilities (2023 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has reported Total Current Liabilities for 4 consecutive years, with $4.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities changed N/A year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $4.6 million (changed N/A YoY), while the FY2025 annual figure was $4.1 million, up 14.57% from the prior year.
- Total Current Liabilities advanced to $4.6 million in Q1 2026 per MSLE's latest filing, from $4.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $4.6 million in Q1 2026 and bottomed at $2.7 million in Q4 2023.
- Historically, Total Current Liabilities has averaged $3.8 million across 4 years, with a median of $3.9 million in 2024.
- Annual changes were most pronounced in 2024 — Total Current Liabilities jumped 38.63% — and 2025, when it climbed 11.24%.
- Satellos Bioscience's Total Current Liabilities stood at $2.7 million in 2023, then soared by 38.63% to $3.7 million in 2024, then gained by 11.24% to $4.1 million in 2025, then climbed by 11.16% to $4.6 million in 2026.
- Business Quant data shows MSLE's Total Current Liabilities at $4.6 million in Q1 2026, $4.1 million in Q4 2025, and $3.7 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Satellos Bioscience | 208.31 Mn | 208.31 Mn | - | 5.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.56 Mn |
| Dec 31, 2025 | 4.11 Mn |
| Dec 31, 2024 | 3.69 Mn |
| Dec 31, 2023 | 2.66 Mn |